PMSA 2020 Virtual Conference
We are attending PMSA Virtual 2020! Check out our PRECISIONxtract virtual booth to learn more about our proprietary RApid Payer, Provider, & Patient Integrated Data (RAPID) Ecosystem and learn how to connect your data to unlock insights.
Webinar: 2020 Social Determinants of Health Series–Assessing and Addressing Social Determinants of Health During a Pandemic
This second webinar in our SDOH series will feature KOLs emphasizing applied learnings in the SDOH and population health fields. The session will address collaborative patient engagement: how styles of communication, analytics, telemedicine and PHM are tackling social risks and engaging patients in the pandemic/infodemic era.
Webinar: Considerations for Internal Versus External Manufacturing for Developing Cell and Gene Therapies
Manufacturing has been widely recognized as a bottleneck to bring advanced cell and gene therapies to the patients and families in need. The question is, should organizations stay the course internally, or look externally for their manufacturing needs?
Virtual ISPOR Europe 2020
Congratulations to PRECISIONadvisors and PRECISIONheor for presenting more than a dozen posters and panels at Virtual ISPOR Europe 2020, 16 – 19 November, 2020.
HLTH Conference Video: The Science & Politics of Developing a COVID-19 Vaccine & Treatment
Changes in mortality associated with cancer drug approvals in the United States from 2000 to 2016
Multiple factors have contributed to recent reductions in cancer mortality, including declines in smoking rates, treatment advances and better screening. But a key question remains: how much have recent developments in oncology treatments contributed to the decline of cancer mortality in the USA?
AJMC Center for Biosimilars: How to Encourage Biosimilar Uptake, Cultural Changes and Formulary Placement
A deep dive into the future of biosimilars: In this In this exclusive 2-part video interview for AJMC’s Center for Biosimilars, editor Matthew Gavidia speaks with PRECISIONvalue’s Ryan Cox to discuss what employers can do to encourage biosimilar uptake, the cultural changes that are needed to make it happen, and whether midsize employers can participate in payer discussions on formulary placement.
Driving Value in the Era of Biosimilars – What Payers & Manufacturers Can Do to Support Employers
The complexities and misaligned incentives within our healthcare system have affected the pace of biosimilar adoption in the US.
Charting A Course Into The Unknown: Manufacturer Considerations In Gene Therapy
The gene therapy market is still in its infancy but poised for significant growth, with an approximate 25% increase in therapies in the pipeline as compared to 2018. However, the launch of a gene therapy is an event with limited case examples to follow and numerous unique considerations.
How the value of innovation will be redefined in 2021
The value of innovation in 2021: There will be a growing need for innovators to justify the value of their products to multiple stakeholders next year, with an increased focus on a treatment’s societal value, how innovation interacts with digital technologies, and whether new innovations are able to reduce existing health outcome inequalities.